Reverse Phase High Pressure Liquid Chromatographic Determination of Rifampin Quinone and Hydrazone in Anti-tuberculosis Fixed-Dose Formulations Containing Sodium Ascorbate as Anti-oxidant

Purpose : To establish the method for the analysis of rifampin quinone and hydrazone in fixeddose combination tablets (FDC) containing rifampicin with or without sodium ascorbate as an additive. Methods : The International Pharmacopoeial (IP) method for the estimation of rifampin quinone in FDC was modified. The extraction solvent (methanol/buffer mixture) of the IP method was replaced with ethyl acetate, in order to stabilize rifampin quinone in sample solutions of FDC containing sodium ascorbate as an ingredient. Results : Rifampin quinone in FDC samples containing sodium ascorbate, which is not detectable in the IP method, was found to be 1.15 % (4-FDC), 1.52 % (3-FDC) and 1.60 % (2-FDC) using the modified method. Recovery of rifampin quinone in spiked samples of FDCs was practically nil in IP method whereas the recovery was 99.95%, 99.39 and 99.02 % for 4–FDC, 3-FDC and 2-FDC, respectively. Conclusion : This modified method was suitable for the determination of rifampin quinone in fixed-dose formulations of rifampin both in the presence and absence of sodium ascorbate. The method is specific, precise, accurate, robust, rugged and gives a linear response for the quantitative estimation of rifampin quinone and hydrazone in fixed-dose combination tablets containing rifampin. Keywords : Fixed dose combination; Rifampin quinone; Tuberculosis; Sodium ascorbate; Quantitative determination; HPLC Tropical Journal of Pharmaceutical Research December 2010; 9 (6): 587-593

[1]  Wei Zhang,et al.  HPLC determination of rifampicin and related compounds in pharmaceuticals using monolithic column. , 2008, Journal of pharmaceutical and biomedical analysis.

[2]  I. L. Brunetti,et al.  Horseradish peroxidase-catalyzed oxidation of rifampicin: reaction rate enhancement by co-oxidation with anti-inflammatory drugs. , 2005, Biological and Pharmaceutical Bulletin.

[3]  Saranjit Singh,et al.  Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin. , 2003, Journal of pharmaceutical and biomedical analysis.

[4]  Saranjit Singh,et al.  Behavior of Decomposition of Rifampicin in the Presence of Isoniazid in the pH Range 1–3 , 2003, Drug development and industrial pharmacy.

[5]  R. Shankar,et al.  A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. , 2001, International journal of pharmaceutics.

[6]  B. S. Rao,et al.  Development Of Dissoulution Medium For Rifampicin Sustained Release Formulations , 2001 .

[7]  W. Wilson,et al.  High Performance Liquid Chromatographic Analysis of Rifampin and Related Impurities in Pharmaceutical Formulations , 1979 .

[8]  H. Bolt,et al.  Implication of rifampicin-quinone in the irreversible binding of rifampicin to macromolecules. , 1976, Xenobiotica; the fate of foreign compounds in biological systems.